Gadodiamide Injection — Competitive Intelligence Brief

Gadodiamide Injection (Gadodiamide Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based contrast agent. Area: Diagnostic Imaging.

phase 3 Gadolinium-based contrast agent Water protons (T1 relaxation enhancement) Diagnostic Imaging Small molecule

Target snapshot

Gadodiamide Injection (Gadodiamide Injection) — GE Healthcare. Gadodiamide is a gadolinium-based contrast agent that enhances magnetic resonance imaging by shortening the T1 relaxation time of water protons in tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gadodiamide Injection TARGET	Gadodiamide Injection	GE Healthcare	phase 3	Gadolinium-based contrast agent	Water protons (T1 relaxation enhancement)
Gadavist	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]		2011-01-01
Gadopentetate-Dimeglumine 0.05 mmol	Gadopentetate-Dimeglumine 0.05 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water protons (T1 relaxation enhancement)
Gadopentetate-Dimeglumine 0.0125 mmol	Gadopentetate-Dimeglumine 0.0125 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
gadoxetic acid enhanced liver MRI	gadoxetic acid enhanced liver MRI	Seoul National University Hospital	marketed	Gadolinium-based contrast agent	Organic anion transporter 1B1/1B3 (OATP1B1/1B3)
Gadovist®/Gadavist®	Gadovist®/Gadavist®	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
Gadobutrol (Gadovist/Gadavist)	Gadobutrol (Gadovist/Gadavist)	Insel Gruppe AG, University Hospital Bern	marketed	Gadolinium-based contrast agent (GBCA)	Water proton relaxation (T1 relaxation enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based contrast agent class)

1. Guerbet · 4 drugs in this class
2. Bayer · 4 drugs in this class
3. Paracelsus Medical University · 2 drugs in this class
4. GE Healthcare · 1 drug in this class
5. Bracco Diagnostics, Inc · 1 drug in this class
6. Seoul National University Hospital · 1 drug in this class
7. Shanghai Shengdi Pharmaceutical Co., Ltd · 1 drug in this class
8. The Central Hospital of Lishui City · 1 drug in this class